Form IRANNOTICE NOVO NORDISK A S
Tweet
Share
E-mailU.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
February 4, 2026
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.
Sincerely,
| /s/ Maziar Mike Doustdar | /s/ Karsten Munk Knudsen | |||||||
Maziar Mike Doustdar President and chief executive officer | Karsten Munk Knudsen Executive vice president and chief financial officer | |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Nordisk (NVO) call put ratio 2.5 call to 1 put into quarter results
- Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into quarter results
- Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
